AstraZeneca Reloads its Pipeline with Ardea Deal, Could be Still Hunting

Bruce V. Bigelow AstraZeneca (NYSE: AZN), the global pharmaceutical giant based in London, is replenishing its drug pipeline with its acquisition of San Diego’s Ardea Biosciences (NASDAQ: RDEA), which was disclosed by both companies earlier today.
Read the full story: Xconomy Life Sciences